Vor Bio completes UPSTREAM MG enrolment and launches oMG trial
Vor Bio has completed enrolment in UPSTREAM MG, its global Phase 3 registrational trial of telitacicept in generalised myasthenia gravis (gMG), and announced a second registrational programme, UPSTREAM oMG, targeting the ocular form of the disease. Topline results from UPSTREAM MG's 24-week primary endpoint are expected in the first half of 2027, the NASDAQ-listed company said.
The enrolment completion is a meaningful operational milestone for a clinical-stage company running a multi-country trial in a rare neuromuscular indication. Vor Bio has not disclosed total patient numbers, site count, or geographic distribution, but described the programme as global in scope.
The science behind telitacicept
Telitacicept is a recombinant fusion protein that inhibits two cytokines, BAFF (BLyS) and APRIL, which are essential to the survival of B cells and plasma cells. By suppressing both targets simultaneously, the drug is designed to reduce autoreactive B-cell activity and the production of autoantibodies that drive conditions such as gMG and ocular MG. The dual-target mechanism differentiates telitacicept from several approved therapies that work further downstream, primarily by reducing circulating immunoglobulin G rather than modulating the upstream B-cell compartment.
James F. Howard Jr., professor at UNC School of Medicine, described the mechanism as "a broader approach than current downstream therapies focused primarily on circulating IgG reduction and without complete B-cell depletion." That framing positions telitacicept in contrast to neonatal Fc receptor (FcRn) inhibitors such as efgartigimod and rozanolixizumab, which have received regulatory approval in gMG in recent years and act on antibody recycling rather than B-cell survival.
UPSTREAM MG uses change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at week 24 as its primary endpoint. Key secondary endpoints include Quantitative Myasthenia Gravis (QMG) score, muscle strength measures, and patient-reported outcomes. A 48-week open-label extension follows the placebo-controlled period. The design draws on a Phase 3 trial run by RemeGen, telitacicept's originator, in China, where the drug demonstrated statistically significant improvements in both MG-ADL and QMG scores at week 24, with continued clinical improvement through week 48 in the open-label period.
Ocular MG: an underserved subset
Ocular myasthenia gravis, in which weakness is confined to the muscles controlling the eyes and eyelids, causes ptosis and diplopia and can substantially impair reading, driving, and working. There are no dedicated regulatory approvals specifically for oMG in major markets, and standard of care typically relies on corticosteroids, acetylcholinesterase inhibitors, or off-label use of agents approved for gMG. Vor Bio intends to initiate UPSTREAM oMG with first patient dosing in H1 2027, overlapping with the UPSTREAM MG readout window.
The competitive landscape in gMG has changed markedly since the approval of eculizumab in 2017. FcRn inhibitors, complement inhibitors, and neonatal Fc receptor antagonists now populate a field that was once largely reliant on immunosuppressants and cholinesterase inhibitors. Telitacicept's BAFF/APRIL dual inhibition has received approval in China for gMG, SLE, rheumatoid arthritis, IgA nephropathy, and Sjögren's disease, giving Vor Bio a substantial body of safety and efficacy data to support its global regulatory submissions. Whether that translated evidence base will satisfy the FDA, EMA, and PMDA without additional bridging requirements will be a key question investors will focus on ahead of the 2027 readout.
Vor Bio's broader ambition is to build a multi-indication autoimmune franchise around telitacicept; a Phase 3 programme in Sjögren's disease is running in parallel with the two MG studies.